Overall treatment discontinuation rates were similar across the retatrutide and placebo treatment arms
The drugs molecular structure has been public for years, since Eli Lilly published it in a research paper in 2022
GLP-1 medications are typically administered once weekly via a subcutaneous injection, meaning a small injection just beneath the skin that causes minimal discomfort compared to intramuscular injections
That means that a big open question is whether the side effect profiles may differ in subgroups of people that scientists have not directly studied, which include a large swath of people now taking these drugs to lose only about 10 to 15 pounds
Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.
on the other hand, the comparison with insulin degludec showed that although insulin, titrated during the study, obtained a better result on fasting blood glucose, treatment with tirzepatide 10 and 15 mg demonstrated better control on all other points of glucose profile [60]
